{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:32:40Z","timestamp":1790728360833,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00432-021-03693-5","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T11:02:46Z","timestamp":1624014166000},"page":"975-984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study"],"prefix":"10.1007","volume":"148","author":[{"given":"V.","family":"Leclerc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Herledan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Marchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Baudouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gouraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Caffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Larbre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lazareth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rioufol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9181-4231","authenticated-orcid":false,"given":"F.","family":"Ranchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"issue":"2","key":"3693_CR1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/ajco.12013","volume":"9","author":"M Alexander","year":"2013","unstructured":"Alexander M, Teoh KC, Lingaratnam S, Kirsa S, Mellor JD (2013) Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital: Thromboprophylaxis in multiple myeloma. Asia Pac J Clin Oncol 9(2):169\u2013175","journal-title":"Asia Pac J Clin Oncol"},{"issue":"2","key":"3693_CR2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/cncr.26302","volume":"118","author":"EJ Anaissie","year":"2012","unstructured":"Anaissie EJ, Coleman EA, Goodwin JA, Kennedy RL, Lockhart KD, Stewart CB et al (2012) Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. Cancer 118(2):549\u2013557","journal-title":"Cancer"},{"issue":"4","key":"3693_CR3","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1078155218758500","volume":"25","author":"SM Anderson","year":"2019","unstructured":"Anderson SM, Beck B, Sterud S, Lockhorst R, Ngorsuraches S (2019) Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma. J Oncol Pharm Pract 25(4):806\u2013812","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"3693_CR51","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/pds.4180","volume":"26","author":"Aurore Palmaro","year":"2017","unstructured":"Aurore, Palmaro Marie-Eve, Roug\u00e9-Bugat Martin, Gauthier Fabien, Despas Guillaume, Moulis Maryse, Lapeyre-Mestre (2017) Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database. Pharmacoepidemiology and Drug Safety 26(5) 578-586 https:\/\/doi.org\/10.1002\/pds.4180","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"3693_CR4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.critrevonc.2018.06.015","volume":"129","author":"A Bellesoeur","year":"2018","unstructured":"Bellesoeur A, Thomas-Schoemann A, Allard M, Smadja D, Vidal M, Alexandre J et al (2018) Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences. Crit Rev Oncol Hematol 129:102\u2013112","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"3693_CR5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/ehm.12.52","volume":"5","author":"EM Boyle","year":"2012","unstructured":"Boyle EM, Fouquet G, Manier S, Gauthier J, Noel MP, Borie C et al (2012) Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis. Expert Rev Hematol 5(6):617\u2013626","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"3693_CR6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","volume":"9","author":"M Carrier","year":"2011","unstructured":"Carrier M, Le Gal G, Tay J, Wu C, Lee AY (2011) Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost JTH 9(4):653\u2013663","journal-title":"J Thromb Haemost JTH"},{"issue":"1","key":"3693_CR7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/rth2.12161","volume":"3","author":"E Chalayer","year":"2019","unstructured":"Chalayer E, Tardy-Poncet B, Karlin L, Chapelle C, Montmartin A, Piot M et al (2019) Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: An observational cohort study. Res Pract Thromb Haemost 3(1):89\u201398","journal-title":"Res Pract Thromb Haemost"},{"key":"3693_CR8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fonc.2019.00045","volume":"9","author":"RF Cornell","year":"2019","unstructured":"Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Patton D et al (2019) Apixaban for primary prevention of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory therapy. Front Oncol 9:45","journal-title":"Front Oncol"},{"issue":"2","key":"3693_CR9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/1078155215569555","volume":"22","author":"RJ Dede","year":"2016","unstructured":"Dede RJ, Pruemer JM (2016) Comparing venous thromboembolism prophylactic strategies for ambulatory multiple myeloma patients on immunomodulatory drug therapy. J Oncol Pharm Pract off Publ Int Soc Oncol Pharm Pract 22(2):248\u2013255","journal-title":"J Oncol Pharm Pract off Publ Int Soc Oncol Pharm Pract"},{"issue":"7","key":"3693_CR10","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1023\/A:1011132808904","volume":"12","author":"MA Dimopoulos","year":"2001","unstructured":"Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C et al (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12(7):991\u2013995","journal-title":"Ann Oncol"},{"issue":"11","key":"3693_CR11","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","volume":"23","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA et al (2009) Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23(11):2147\u20132152","journal-title":"Leukemia"},{"issue":"9","key":"3693_CR12","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bulcan.2017.04.005","volume":"104","author":"A Doug\u00e9","year":"2017","unstructured":"Doug\u00e9 A, Lemal R, Chaleteix C (2017) Pomalidomide for multiple myeloma. Bull Cancer (paris) 104(9):707\u2013713","journal-title":"Bull Cancer (paris)"},{"issue":"10068","key":"3693_CR13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP et al (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet Lond Engl 389(10068):519\u2013527","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"3693_CR14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/17474086.2019.1604214","volume":"12","author":"D Fotiou","year":"2019","unstructured":"Fotiou D, Gavriatopoulou M, Ntanasis-Stathopoulos I, Migkou M, Dimopoulos MA, Terpos E (2019) Updates on thrombotic events associated with multiple myeloma. Expert Rev Hematol 12(5):355\u2013365","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"3693_CR15","first-page":"1","volume":"14","author":"J Fox","year":"2005","unstructured":"Fox J, The R (2005) Commander: a basic-statistics graphical user interface to R. J Stat Softw 14(1):1\u201342","journal-title":"J Stat Softw"},{"issue":"9","key":"3693_CR16","first-page":"1141","volume":"89","author":"M Galli","year":"2004","unstructured":"Galli M, Elice F, Crippa C, Comotti B, Rodeghiero F, Barbui T (2004) Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica 89(9):1141\u20131142","journal-title":"Haematologica"},{"key":"3693_CR17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.phrs.2018.07.016","volume":"135","author":"P Gelosa","year":"2018","unstructured":"Gelosa P, Castiglioni L, Tenconi M, Baldessin L, Racagni G, Corsini A et al (2018) Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res 135:60\u201379","journal-title":"Pharmacol Res"},{"key":"3693_CR49","unstructured":"IMWG website. https:\/\/www.myeloma.org\/resource-library\/imwg-guidelines-prevention-thalidomide-lenalidomide-associated-thrombosis-myeloma"},{"key":"3693_CR50","unstructured":"IMWG website. https:\/\/www.myeloma.org\/resource-library\/imwg-guidelines-prevention-thalidomide-lenalidomide-associated-thrombosis-myeloma"},{"issue":"19","key":"3693_CR18","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","volume":"354","author":"R Knight","year":"2006","unstructured":"Knight R, DeLap RJ, Zeldis JB (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354(19):2079\u20132080","journal-title":"N Engl J Med"},{"key":"3693_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02354-7","author":"G Lapietra","year":"2021","unstructured":"Lapietra G, Serrao A, Fazio F, Petrucci MT, Chistolini A (2021) Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going? J Thromb Thrombolysis. https:\/\/doi.org\/10.1007\/s11239-020-02354-7","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"3693_CR20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.thromres.2015.09.021","volume":"136","author":"S-E Lee","year":"2015","unstructured":"Lee S-E, Jeon Y-W, Yoon J-H, Cho B-S, Eom K-S, Kim Y-J et al (2015) Clinical outcomes of venous thromboembolism with dalteparin therapy in multiple myeloma patients. Thromb Res 136(5):974\u2013979","journal-title":"Thromb Res"},{"issue":"Suppl 1","key":"3693_CR21","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.thromres.2012.08.279","volume":"130","author":"X Leleu","year":"2012","unstructured":"Leleu X (2012) Thrombosis in myeloma treated with IMiDs. Thromb Res 130(Suppl 1):S63-65","journal-title":"Thromb Res"},{"issue":"2","key":"3693_CR22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.revmed.2004.06.017","volume":"26","author":"X Leleu","year":"2005","unstructured":"Leleu X, Micol JB, Guieze R, Berthon C, Kuhnovsky F, Terriou L et al (2005) Thalidomide\u00a0: m\u00e9canismes d\u2019action et indications en h\u00e9matologie. Rev M\u00e9decine Interne. 26(2):119\u2013127","journal-title":"Rev M\u00e9decine Interne."},{"issue":"4","key":"3693_CR23","first-page":"844","volume":"110","author":"X Leleu","year":"2013","unstructured":"Leleu X, Rodon P, Hulin C, Daley L, Dauriac C, Hacini M et al (2013) MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thromb Haemost 110(4):844\u2013851","journal-title":"Thromb Haemost"},{"issue":"7","key":"3693_CR24","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","volume":"3","author":"W Li","year":"2017","unstructured":"Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME et al (2017) Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review. JAMA Oncol 3(7):980","journal-title":"JAMA Oncol"},{"issue":"7","key":"3693_CR25","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","volume":"17","author":"A Li","year":"2019","unstructured":"Li A, Wu Q, Luo S, Warnick GS, Zakai NA, Libby EN et al (2019) Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma. J Natl Compr Canc Netw 17(7):840\u2013847","journal-title":"J Natl Compr Canc Netw"},{"issue":"17","key":"3693_CR26","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","volume":"31","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP et al (2013) Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol 31(17):2189\u20132204","journal-title":"J Clin Oncol"},{"issue":"14","key":"3693_CR27","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2010.32.5878","volume":"29","author":"P Moreau","year":"2011","unstructured":"Moreau P, Avet-Loiseau H, Harousseau J-L, Attal M (2011a) Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol off J Am Soc Clin Oncol 29(14):1898\u20131906","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"issue":"22","key":"3693_CR28","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","volume":"118","author":"P Moreau","year":"2011","unstructured":"Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C et al (2011b) Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118(22):5752\u20135758","journal-title":"Blood"},{"issue":"20","key":"3693_CR29","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","volume":"125","author":"P Moreau","year":"2015","unstructured":"Moreau P, Attal M, Facon T (2015) Frontline therapy of multiple myeloma. Blood 125(20):3076\u20133084","journal-title":"Blood"},{"issue":"5","key":"3693_CR30","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/pds.4180","volume":"26","author":"A Palmaro","year":"2017","unstructured":"Palmaro A, Roug\u00e9-Bugat M-E, Gauthier M, Despas F, Moulis G, Lapeyre-Mestre M (2017) Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database. Pharmacoepidemiol Drug Saf 26(5):578\u2013586","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"3693_CR31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/2042098612452291","volume":"3","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Palladino C (2012) Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. Ther Adv Drug Saf 3(5):255\u2013266","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"3693_CR32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414\u2013423","journal-title":"Leukemia"},{"issue":"6","key":"3693_CR33","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G et al (2014) International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 32(6):587\u2013600","journal-title":"J Clin Oncol"},{"issue":"6","key":"3693_CR34","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ajh.25459","volume":"94","author":"B Pegourie","year":"2019","unstructured":"Pegourie B, Karlin L, Benboubker L, Orsini-Piocelle F, Tiab M, Auger-Quittet S et al (2019) Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. Am J Hematol 94(6):635\u2013640","journal-title":"Am J Hematol"},{"issue":"4","key":"3693_CR35","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2141.2008.06997.x","volume":"141","author":"R Popat","year":"2008","unstructured":"Popat R, Oakervee HE, Hallam S, Curry N, Odeh L, Foot N et al (2008) Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 141(4):512\u2013516","journal-title":"Br J Haematol"},{"issue":"21","key":"3693_CR36","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","volume":"20","author":"SV Rajkumar","year":"2002","unstructured":"Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20(21):4319\u20134323","journal-title":"J Clin Oncol"},{"issue":"3","key":"3693_CR37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","volume":"24","author":"SV Rajkumar","year":"2006","unstructured":"Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, Eastern Cooperative Oncology Group (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol off J Am Soc Clin Oncol. 24(3):431\u2013436","journal-title":"J Clin Oncol off J Am Soc Clin Oncol."},{"issue":"1","key":"3693_CR38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11(1):29\u201337","journal-title":"Lancet Oncol"},{"issue":"4","key":"3693_CR39","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2008-12-196238","volume":"114","author":"P Richardson","year":"2009","unstructured":"Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D et al (2009) Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 114(4):772\u2013778","journal-title":"Blood"},{"issue":"5","key":"3693_CR40","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS et al (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116(5):679\u2013686","journal-title":"Blood"},{"issue":"11","key":"3693_CR41","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","volume":"94","author":"KM Sanfilippo","year":"2019","unstructured":"Sanfilippo KM, Luo S, Wang T, Fiala M, Schoen M, Wildes TM et al (2019) Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol 94(11):1176\u20131184","journal-title":"Am J Hematol"},{"issue":"15_suppl","key":"3693_CR42","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1200\/JCO.2018.36.15_suppl.8051","volume":"36","author":"MW Schoen","year":"2018","unstructured":"Schoen MW, Luo S, Gage B, Carson KR, Sanfilippo KM (2018) Association of venous thromboembolism with increased mortality in patients with multiple myeloma. J Clin Oncol 36(15_suppl):8051\u20138051","journal-title":"J Clin Oncol"},{"issue":"4","key":"3693_CR43","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15684","volume":"183","author":"D Swan","year":"2018","unstructured":"Swan D, Rocci A, Bradbury C, Thachil J (2018) Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations. Br J Haematol 183(4):538\u2013556","journal-title":"Br J Haematol"},{"issue":"1","key":"3693_CR44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11239-019-01809-w","volume":"48","author":"K Takaishi","year":"2019","unstructured":"Takaishi K, Tsukamoto S, Ohwada C, Takeuchi M, Kawasaki Y, Nagai Y et al (2019) Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis. J Thromb Thrombolysis 48(1):141\u2013148","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"3693_CR45","first-page":"235","volume":"12","author":"M Wang","year":"2007","unstructured":"Wang M, Giralt S, Delasalle K, Handy B, Alexanian R (2007) Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematol Amst Neth 12(3):235\u2013239","journal-title":"Hematol Amst Neth"},{"issue":"4","key":"3693_CR46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11899-016-0331-4","volume":"11","author":"GF Westin","year":"2016","unstructured":"Westin GF, Dias AL, Go RS (2016) Exploring big data in hematological malignancies: challenges and opportunities. Curr Hematol Malig Rep 11(4):271\u2013279","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"3693_CR47","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-2003-40965","volume":"29","author":"M Zangari","year":"2003","unstructured":"Zangari M (2003) The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 29(3):275\u2013282","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"3693_CR48","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3816\/CLM.2003.n.011","volume":"4","author":"M Zangari","year":"2003","unstructured":"Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L et al (2003) Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma 4(1):32\u201335","journal-title":"Clin Lymphoma"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03693-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03693-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03693-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T22:04:09Z","timestamp":1647554649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03693-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3693"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03693-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,18]]},"assertion":[{"value":"11 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was registered in the National Data Protection Commission register authorized for Hospices Civils de Lyon (n\u00b0 15\u2013122).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}